What You Should Know:
– Pangea Biomed, the startup behind the world’s most advanced cancer response predictor, ENLIGHT, is announcing a strategic collaboration with the Sharett Institute of Oncology and Hadassah Cancer Research Institute (HCRI) at the Hadassah University Hospital Ein-Kerem and Ultima Genomics, the developer of a revolutionary architecture for high-throughput genomic sequencing.
– This partnership aims to enhance the accuracy and effectiveness of solid tumor cancer treatment predictions through advanced genetic and transcriptomic profiling.
Pangea Biomed and Hadassah Partnership Enhances Precision Oncology for Solid Tumor Patients
Founded in 2018, Pangea Biomed developed ENLIGHT, the world’s most advanced multi-cancer, multi-therapy response predictor. By leveraging machine learning and deep RNA analysis, Pangea Biomed maps tumor molecular signatures to dynamically and adaptively personalize cancer care. The company’s mission is to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to enhance treatment success.
Solid tumors, including breast, lung, prostate, and kidney cancers, represent approximately 90% of adult human cancers. These tumors are challenging to treat due to their genetic heterogeneity and potential for metastasis. Effective treatment often requires a combination of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy, tailored to the tumor’s specific genetic profile.
In a significant initiative led by Hadassah, nearly all solid tumor patients at the Sharett Institute of Oncology undergoing biopsies will receive comprehensive genetic profiling with FoundationOne, a tissue-based broad companion diagnostic DNA test. This profiling will inform therapy choices. Pangea Biomed will utilize RNA data obtained by Ultima Genomics and whole-slide histopathology scans as inputs to its AI-driven ENLIGHT platform. The resulting ENLIGHT reports, combined with Hadassah’s clinical output and analysis, are expected to enhance treatment decisions for these patients.
The partnership between Pangea Biomed and Hadassah includes several key components:
– Hadassah will provide essential biological samples and conduct comprehensive patient follow-ups.
– Hadassah experts will perform profound analyses of the dataset, including DNA test results, clinical data, and patient information.
– Hadasit, the Technology Transfer Company and innovation arm of Hadassah Hospitals, is facilitating this collaboration and signing the agreement on behalf of Hadassah.
– This partnership builds on Pangea Biomed’s existing collaboration with researchers at Hadassah to analyze data from patients treated with immunotherapy at the Sharett Institute of Oncology. The results, which demonstrated that ENLIGHT Matching Scores outperform standard biomarkers, were recently presented at the ASCO 2024 Annual Meeting.
“This partnership marks a significant step forward in the fight against solid tumors,” said Tuvik Beker, CEO of Pangea Biomed. “By integrating comprehensive DNA, RNA, and imaging data, we are creating an unparalleled dataset that will not only benefit patients directly but also fuel numerous future research endeavors and clinical trials.”
The collaboration is designed as a long-term, multi-year project to produce ENLIGHT reports for more than 2,000 patients annually.
